Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) shares passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.01 and traded as low as $0.00. Nascent Biotech shares last traded at $0.00, with a volume of 87,000 shares trading hands.
Nascent Biotech Price Performance
The stock’s 50-day moving average is $0.01 and its two-hundred day moving average is $0.03.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Recommended Stories
- Five stocks we like better than Nascent Biotech
- Investing In Preferred Stock vs. Common Stock
- AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Why Call Option Traders Are Targeting This Dividend ETF Now
- What is the NASDAQ Stock Exchange?
- Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
